Search research articles
Contact Us
Filters
Showing results (51-60 of 79) with videos related to
Page
of 8
Sort By:
Blood
|
October 24, 2002
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
Dietger Niederwieser, Michael Maris, Judith A Shizuru, et al.
Leukemia
|
January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Elias Jabbour, Jane Apperley, Jorge Cortes, et al.
Leukemia
|
September 2, 2024
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Elias Jabbour, Jane Apperley, Jorge Cortes, et al.
American Journal of Hematology
|
September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia
Hagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
Journal of Hematology & Oncology
|
January 7, 2022
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
James L Januzzi, Joseph M Garasic, Scott E Kasner, et al.
Blood
|
March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Journal of Hematology & Oncology
|
March 23, 2022
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
James L Januzzi, Joseph M Garasic, Scott E Kasner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2008
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Neil P Shah, Hagop M Kantarjian, Dong-Wook Kim, et al.
Hemasphere
|
February 24, 2021
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
Peter Valent, Alberto Orfao, Stefan Kubicek, et al.
Blood
|
August 18, 2021
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial
Jorge Cortes, Jane Apperley, Elza Lomaia, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 79) with videos related to
Sort By:
Page
of 8
Blood
|
October 24, 2002
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
Dietger Niederwieser, Michael Maris, Judith A Shizuru, et al.
Leukemia
|
January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Elias Jabbour, Jane Apperley, Jorge Cortes, et al.
Leukemia
|
September 2, 2024
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
Elias Jabbour, Jane Apperley, Jorge Cortes, et al.
American Journal of Hematology
|
September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia
Hagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
Journal of Hematology & Oncology
|
January 7, 2022
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
James L Januzzi, Joseph M Garasic, Scott E Kasner, et al.
Blood
|
March 9, 2006
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes, Michael Deininger, Andreas Hochhaus, et al.
Journal of Hematology & Oncology
|
March 23, 2022
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
James L Januzzi, Joseph M Garasic, Scott E Kasner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2008
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Neil P Shah, Hagop M Kantarjian, Dong-Wook Kim, et al.
Hemasphere
|
February 24, 2021
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
Peter Valent, Alberto Orfao, Stefan Kubicek, et al.
Blood
|
August 18, 2021
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial
Jorge Cortes, Jane Apperley, Elza Lomaia, et al.
Page
of 8